AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8800872
Drug: Sodium ironedetate
RxNorm normalized name: Sodium ironedetate
DrugBank: Sodium feredetate (DB13381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ironedetate (Sytron) administered rectally at a concentration of 7.6 mg ml‐1
Trial: 1353804
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 plus 750 mg/m2 cyclophosphamide (high dose)
Trial: 1353804
Drug: Cisplatin 50
RxNorm normalized name: cisplatin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 50 mg/m2 plus 750 mg/m2 cyclophosphamide (low dose)
Trial: 22820371
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (25‐hydroxy vitamin D); specific dosage and duration not mentioned.
Trial: 2459525
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg/day)
Trial: 11181473
Drug: Endothelin A
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelin A receptor blocker LU 135252 (30 mg/d)
Trial: 11181473
Drug: Endothelin A
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelin A receptor blocker LU 135252 (300 mg/d)
Trial: 9828759
Drug: 0 g/200
RxNorm normalized name: sodium polystyrene sulfonate 50 g/200 mL rectal enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/200 ml phytic acid (totally dephytinized soya milk)
Trial: 9828759
Drug: 0.26 g/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.26 g/200 ml phytic acid (natural phytic acid content)
Trial: 9828759
Drug: 0.13 g/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.13 g/200 ml phytic acid (half dephytinized soya milk)
Trial: 8006401
Drug: Terlipressin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (2 mg every 6 h)
Trial: 8006401
Drug: Vasopressin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressin (0.4 to 0.8 unit per min) plus transdermal nitroglycerin (20 to 80 mg)
Trial: 429083
Drug: Placebo (Elixophyllin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Elixophyllin Elixir, 250 mg)
Trial: 429083
Drug: Isoproterenol inhalation
RxNorm normalized name: Isoproterenol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol inhalation
Trial: 25919061
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg bid
Trial: 17292948
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg bid
Trial: 17292948
Drug: Rivaroxaban 30
RxNorm normalized name: rivaroxaban 30-Day Starter Pack (42-15 MG Oral Tablets & 9-20 MG Oral Tablets)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 30 mg bid
Trial: 17292948
Drug: Rivaroxaban 30
RxNorm normalized name: rivaroxaban 30-Day Starter Pack (42-15 MG Oral Tablets & 9-20 MG Oral Tablets)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 30 mg od
Trial: 17292948
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg od
Trial: 20062915
Drug: Rivaroxaban (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (all doses)
Trial: 8299092
Drug: Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care plus melatonin (20 mg/day at 8:00 p.m. orally)
Trial: 8299092
Drug: Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care alone (steroids plus anticonvulsant agents)
Trial: 30578714
Drug: Treatment according
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment according to a protocol for precursor lymphoblastic lymphoma
Trial: 1484577
Drug: EACA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EACA treatment before operation
Trial: 1484577
Drug: No EACA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No EACA treatment
Trial: 20947098
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone treatment during relapse
Trial: 17186737
Drug: Basal hypoglycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal hypoglycemic treatment (Control)
Trial: 14617116
Drug: Atropine and
RxNorm normalized name: atropine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine and ketamine before propofol infusion
Trial: 10709427
Drug: Intranasal nafarelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal nafarelin acetate (NA) 800 micrograms/d
Trial: 10709427
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (LA) 0.5 mg/d
Trial: 7019929
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg glucosamine sulphate (injectable)
Trial: 7019929
Drug: Oral glucosamine
RxNorm normalized name: glucosamine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucosamine capsules (6 x 250 mg daily)
Trial: 24754142
Drug: Placebo (oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral)
Trial: 7019929
Drug: Piperazine/chlorbutanol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperazine/chlorbutanol combination (intravenous or intramuscular)
Trial: 19680634
Drug: MDMA (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (1.5 mg/kg)
Trial: 19680634
Drug: MDMA (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (0.75 mg/kg)
Trial: 24694926
Drug: MDMA (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (0.75 mg/kg) and MDMA (1.5 mg/kg)
Trial: 19686592
Drug: TetraVisc 0.5%
RxNorm normalized name: TetraVisc 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TetraVisc 0.5% (0.5 ml)
Trial: 12511360
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% gel (1 ml)
Trial: 10210927
Drug: Octreotide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (500 micrograms two times a day subcutaneous for six months)
Trial: 7037043
Drug: 1 litre
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 litre of 0.9% sodium chloride solution intravenously over 1 h
Trial: 7037043
Drug: No supplementary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplementary infusion
Trial: 30852882
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITM)
Trial: 27246602
Drug: Anthelmintic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthelmintic treatment
Trial: 18703567
Drug: L-arginine/GHRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine/GHRH
Trial: 18073313
Drug: L-arginine/GHRP-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine/GHRP-2
Trial: 17066505
Drug: Phentermine-HCl 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine-HCl 37.5 mg once daily with behavioral therapy
Trial: 17066505
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily with behavioral therapy
Trial: 10853298
Drug: FA-specific IgE
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FA-specific IgE antibody measurement
Trial: 8704111
Drug: Baseline active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline active kallikrein excretion
Trial: 1793331
Drug: Perindopril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (2 or 4 mg)
Trial: 6133000
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g SASP daily
Trial: 6133000
Drug: 1, 2,
RxNorm normalized name: Pneumococcal 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, 2, or 4 g SASP daily for 6 months
Trial: 6133000
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg prednisolone daily for one week
Trial: 6133000
Drug: Dummy tablets
RxNorm normalized name: cholecalciferol / tricalcium phosphate Chewable Tablet [Caltrate Gummy Bites]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy tablets for one week
Trial: 26837684
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy (n=47)
Trial: 30625462
Drug: Dexlansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole 60 mg
Trial: 17621520
Drug: Potassium bromide
RxNorm normalized name: Potassium Bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium bromide (started at 45 mg/kg, raised to 70 mg/kg)
Trial: 15981008
Drug: Nadroparin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (0.3 ml, 7,500 anti-Xa units)
Trial: 12560610
Drug: Treatment strategy
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment strategy according to American College of Cardiology / American Heart Association practice guidelines (2002)
Trial: 8742865
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (4 x 70 mg.kg‐1 body mass per day mixed with 5 g glucose)
Trial: 8742865
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 x 10 g glucose per day)
Trial: 2506503
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (NTG) at 0.25 micrograms/kg/min
Trial: 2506503
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (NTG) at 0.50 micrograms/kg/min
Trial: 1112210
Drug: Three drugs
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three drugs (cyclophosphamide, methotrexate, and prednisone) given to 49 patients
Trial: 707353
Drug: Zn supplement
RxNorm normalized name: zinc bandage with supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zn supplement
Trial: 28780466
Drug: Cisplatin 50
RxNorm normalized name: cisplatin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 50 mg/m2 (GC50)
Trial: 26037199
Drug: Sinetrol® XPur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinetrol® XPur (900 mg daily for 12 weeks)
Trial: 25300286
Drug: Oral medication
RxNorm normalized name: Oral Medication Syringe 3mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medication
Trial: 12639582
Drug: Pre-treatment preference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment preference for hysterectomy
Trial: 12639582
Drug: Pre-treatment preference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment preference for conservative option
Trial: 12639582
Drug: Factors influencing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors influencing treatment choice
Trial: 1283590
Drug: captopril 25mg
RxNorm normalized name: CAPTOPRIL 25MG TAB
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: captopril 25mg twice daily
Trial: 3571940
Drug: Methylamphetamine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylamphetamine (15 mg, intravenous)
Trial: 3571940
Drug: Control (sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (sterile water, intravenous)
Trial: 18758971
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation pharmacotherapy
Trial: 29364489
Drug: Hindlimb suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hindlimb suspension (HS) for 2 weeks
Trial: 8393389
Drug: Lisinopril therapy
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril therapy
Trial: 11106716
Drug: 180 microg
RxNorm normalized name: Pramipexole (as pramipexole dihydrochloride) 180 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 microg of peginterferon alfa‐2a once weekly
Trial: 11106716
Drug: 90 microg
RxNorm normalized name: Linaclotide 290 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 microg of peginterferon alfa‐2a once weekly
Trial: 11106716
Drug: 3 million
RxNorm normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 million units of interferon alfa‐2a three times weekly
Trial: 9053508
Drug: Monthly regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly regimen of IV LV 20 mg/m2 plus bolus 5‐FU 425 mg/m2 for 5 days every 4 weeks
Trial: 9053508
Drug: Bimonthly regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimonthly regimen of IV LV 200 mg/m2 as a 2-hour infusion followed by bolus 5‐FU 400 mg/m2 and 22-hour infusion 5‐FU 600 mg/m2 for 2 consecutive days every 2 weeks
Trial: 8372720
Drug: Bucillamine (Bu)
RxNorm normalized name: bucillamine
DrugBank: Bucillamine (DB12160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bucillamine (Bu) 3200 mg (single administration)
Trial: 29565771
Drug: α1-receptor blockade
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α1-receptor blockade via oral prazosin (0.05 mg/kg body wt)
Trial: 22192944
Drug: Monthly visits
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly visits by Community Health Workers (CHWs)
Trial: 17371478
Drug: Meal B
RxNorm normalized name: ameal bp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meal B (220 kcal, 5 g lipid)
Trial: 17371478
Drug: Meal C
RxNorm normalized name: Wholemeal chapati
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meal C (474 kcal, 19 g lipid)
Trial: 17371478
Drug: Meal D
RxNorm normalized name: Dimethicone 13 mg in 1 g TOPICAL LOTION [Oatmeal Daily Moisturizing]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meal D (837 kcal, 44 g lipid)
Trial: 10666525
Drug: General practitioner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General practitioner treatment (GP-group), n=63
Trial: 3730264
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose salbutamol treatment
Trial: 20205227
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (in subgroup without epidural blockade or laparoscopic surgery)
Trial: 20205227
Drug: Preoperative carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative carbohydrate (CHO) treatment
Trial: 31867651
Drug: Gradual nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gradual nicotine reduction to 0.04 mg nicotine/g of tobacco
Trial: 14766715
Drug: Dextrose concentrations
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose concentrations (10, 20, 30, 50, and 80 g ml(‐1)) added to 5 g ml(‐1) solutions
Trial: 9024172
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg valsartan
Trial: 9290986
Drug: Sucralfate administration
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate administration
Trial: 21420555
Drug: NASHA Dx
RxNorm normalized name: brompheniramine maleate / dextromethorphan hydrobromide / pseudoephedrine hydrochloride Oral Solution [Myphetane DX]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NASHA Dx (transanal submucosal injections)
Trial: 8590556
Drug: Control situation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control situation (no treatment)
Trial: 1098705
Drug: Synthetic anticholinergic
RxNorm normalized name: Synthetic anticholinergics, quaternary ammonium compounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic anticholinergic drug (SCH 10000)
Trial: 31742366
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity laser therapy (HILT) with a power of 1.6 W and low fluence of 8 J/cm2
Trial: 31282081
Drug: 14-day therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day therapy with levofloxacin (750 mg), clarithromycin-MR (1 g), rabeprazole (60 mg), and bismuth subsalicylate (1,048 mg)
Trial: 31282081
Drug: 7-day therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day therapy with levofloxacin (750 mg), clarithromycin-MR (1 g), rabeprazole (60 mg), and bismuth subsalicylate (1,048 mg)
Trial: 19841844
Drug: Function-centred inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Function-centred inpatient treatment
Trial: 9516063
Drug: Galanin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Galanin infusion (8 microg/Kg/h) in healthy volunteers (group I)
Trial: 9516063
Drug: Galanin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Galanin infusion (8 microg/Kg/h) in cured acromegaly patients (group III)
Trial: 8034992
Drug: Dirithromycin, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dirithromycin, 500 mg once daily
Trial: 8034992
Drug: Erythromycin, 250
RxNorm normalized name: Erythromycin, 250 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin, 250 mg four times daily
Trial: 6419263
Drug: Plasma haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasma haloperidol levels (4.2‐11.0 ng/ml) during the first 14 days of treatment
Trial: 23176984
Drug: Intrathecal 4
RxNorm normalized name: LIORESAL INTRATHECAL 40 MG in 20 ML (2,000 MCG/ML) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 4 mg bupivacaine 0.5% + 25 μg fentanyl
Trial: 21214129
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate 1.2%-benzoyl peroxide 2.5% gel
Trial: 9778066
Drug: Ibutilide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide (1 mg)
Trial: 16351670
Drug: Propafenone (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (70 mg)
Trial: 12361104
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL ipecac syrup
Trial: 27600897
Drug: Prolatan (latanoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolatan (latanoprost 0.005%) once daily in the evening
Trial: 27600897
Drug: Xalatan (latanoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xalatan (latanoprost 0.005%) once daily in the evening
Trial: 20032239
Drug: Platform dropped
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform dropped (8 cm, 0.9 g acceleration)
Trial: 18534330
Drug: Swedish-style massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swedish-style massage therapy
Trial: 25240453
Drug: Rosuvastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 40 mg
Trial: 15215813
Drug: Rosuvastatin 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 80 mg
Trial: 14512129
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 to 80 mg)
Trial: 9308064
Drug: Acetaminophen 15
RxNorm normalized name: acetaminophen 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 15 mg.kg‐1
Trial: 3522770
Drug: Single initial
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single initial 1500 mg dose of rifampin plus daily doses of 100 mg of dapsone
Trial: 27160957
Drug: l-Citrulline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-Citrulline (6 g/d) for 14 d
Trial: 12171842
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg daily oral corticosteroids
Trial: 10404930
Drug: Gradual withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual withdrawal of psychotropic medication
Trial: 10404930
Drug: Continuing to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing to take psychotropic medication
Trial: 31053134
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of daily OCS dose by 5 mg/day
Trial: 22293680
Drug: Low-dose caffeine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose caffeine (200 mg total from 2 pieces of chewing gum) administered at 3 different time points (‐35, ‐5, and +15 minutes) during cycling exercise
Trial: 22293680
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at the other 2 points and at all 3 points in the control trial
Trial: 20216490
Drug: Ultrasound irradiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound irradiation administered to the pressure ulcer through the same dressing used in standard treatment (pulsed ultrasound, 20% duty cycle, 0.5W/cm2, 1MHz or 3MHz, for 10 minutes, five times weekly)